Business Context and Reporting Period
This Form 8-K filing by Biorestorative Therapies, Inc. reports events occurring between May 11, 2016, and June 30, 2016, with the report dated June 24, 2016. The filing details the creation of a direct financial obligation and unregistered sales of equity securities.
Key Financial Metrics and Transactions
- Debt Financing: Borrowed $500,000 from Tuxis Trust on June 30, 2016, at 10% annual interest, maturing July 1, 2017.
- Equity Financing: Issued 97,500 shares of common stock at $4.00 per share between May 18 and June 24, 2016, raising $390,000.
- Debt-for-Equity Swap: Issued 48,142 shares to settle $106,806 of outstanding indebtedness (including accrued interest) between June 6 and June 24, 2016.
- Stock for Services: Issued 13,356 shares valued at $28,553 for services rendered between May 11 and June 27, 2016.
- Warrants Issued:
- 40,000 shares at $4.00 exercise price (5-year term) for the Tuxis Trust loan.
- 97,500 shares at $5.00 exercise price (5-year term) for the equity financing.
The filing does not provide data on revenue, operating profit, cash flow, or overall liquidity positions.
Material Changes and Related Party Transactions
A material related party transaction occurred with Tuxis Trust, a trust established for the benefit of John M. Desmarais, a director and principal shareholder. The loan includes a prepayment clause: if the Company receives net proceeds of $10,000,000 from a single equity or debt financing prior to maturity, the Trust may require prepayment (subject to the new financier's consent).
Outlook, Risks, and Contingencies
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of unregistered securities sales. The Company relied on Section 4(a)(2) and Section 3(a)(9) of the Securities Act of 1933 for exemptions, asserting that investors were accredited and had access to financial information.
Investor Verification Checklist
- Verify the Company's current cash position to assess ability to repay the $500,000 loan by July 1, 2017.
- Confirm the total number of outstanding shares post-issuance to evaluate dilution impact.
- Review the terms of the $10,000,000 financing trigger in the Tuxis Trust note to understand potential liquidity constraints on future capital raises.
- Validate the valuation of the $28,553 stock-for-services transaction against fair market value standards.